Pediatrics
Feature
What did you learn in med school that you disagree with now?
“I was taught the pathology behind arthritic pain, symptoms, signs, and treatment – that it has a genetic component and is inevitable to avoid –...
Latest News
What makes teens choose to use sunscreen?
Of the studies that examined the role of ethnicity on sunscreen use in a systematic review, White high school students were more likely to use...
Feature
Humira biosimilars: Five things to know
The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...
Latest News
New guidelines for MTX use in pediatric inflammatory skin disease unveiled
One of the recommendations states that liver biopsy is not indicated for routine monitoring of pediatric patients taking low-dose MTX.
News from the FDA/CDC
FDA approves ritlecitinib for ages 12 and up for alopecia areata
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...
Guidelines
Systemic JIA and AOSD are the same disease, EULAR says
New recommendations state that the ultimate goal of treatment should be drug-free remission.
Feature
After Yusimry’s steep discount, little clarity on future adalimumab biosimilar pricing
SmithRx, which bills itself as “next-generation pharmacy benefits management,” announced that it will offer Yusimry to its members at a discount...
Latest News
JAK-inhibitor safety in adolescents with AD: Long-term analyses reported
For abrocitinib, "we're starting to get good numbers of [adolescents] who've had about 2 years of exposure," Dr. Lawrence Eichenfield said.
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
Conference Coverage
Low disease state for childhood lupus approaches validation
A new childhood version of the Lupus Low Disease Activity State has been purposefully developed to align with the criteria already used for adults...